Merck - International Biopharmaceutical Industry

news

Merck agrees to license COVID-19 pill widely through pact with patent group

Merck's pill has the potential to alter the course of the pandemic. Earlier this month, the company and partner Ridgeback Biotherapeutics released data showing molnup...

29 October 2021 news COVID-19 | COVID-19 pill

Continue Reading →

news

CDC panel levels playing field for new Merck, Pfizer pneumonia vaccines

This is the first time government advisers have recommended routine use of a pneumococcal vaccine for certain risk groups within the 19-64 age bracket, a move that co...

22 October 2021 news 19-64 age | Cantor Fitzgerald

Continue Reading →

news

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

The Gates Foundation hopes to reduce the gap in time between when wealthy countries and lower-income nations get access to needed medicines like molnupiravir. The fou...

22 October 2021 news COVID-19 | Gates Foundation

Continue Reading →

news

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck's Keytruda is the dominant cancer immunotherapy and, of the seven of its type that are approved, the only that's cleared for use in cervical cancer, the fourth ...

15 October 2021 news cervical cancer | clinical trial

Continue Reading →

news

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase 3 trial, a res...

15 October 2021 news clinical trial | COVID-19

Continue Reading →

news

Insurers sue Merck for ‘monopolistic scheme’ to delay generics of blockbuster cholesterol drug

Insurers Centene and Humana have sued Merck & Co., alleging the drugmaker's "monopolistic scheme" delayed generic versions of its blockbuster cholesterol drug Zet...

30 September 2021 news cholesterol | Crowell & Morning

Continue Reading →

news

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials haven't been com...

30 September 2021 news AstraZeneca | Bristol Myers Squibb

Continue Reading →

news

Merck wins approval for cancer drug acquired in 2019 biotech buyout

Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda w...

20 August 2021 news ArQule | Biotech

Continue Reading →

news

Merck’s Keytruda gets approval in China for advanced melanoma

Melanoma is one of the fastest growing malignant cancers in China, increasing at an annual rate of 3-5 percent, which makes it one of the deadliest diseases in the co...

31 July 2018 news advanced | approval

Continue Reading →

news

Merck inks deal with China’s Xian Janssen for type 2 diabetes drug

China has more than 114 million people living with diabetes, the largest number of any country in the world Global drug giant, Merck signed an agreement with Chi...

13 July 2018 news 2 | China's Xian

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Merck agrees to license COVID-19 pill widely through pact with patent group

CDC panel levels playing field for new Merck, Pfizer pneumonia vaccines

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Insurers sue Merck for ‘monopolistic scheme’ to delay generics of blockbuster cholesterol drug

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

Merck wins approval for cancer drug acquired in 2019 biotech buyout

Merck’s Keytruda gets approval in China for advanced melanoma

Merck inks deal with China’s Xian Janssen for type 2 diabetes drug

International Biopharmaceutical Industry